Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 83 (3), 271-80

Treatment of Acute Migraine Headache

Affiliations
  • PMID: 21302868
Review

Treatment of Acute Migraine Headache

Benjamin Gilmore et al. Am Fam Physician.

Erratum in

  • Am Fam Physician. 2011 Oct 1;84(7):738

Abstract

Migraine headache is a common and potentially debilitating disorder often treated by family physicians. Before diagnosing migraine, serious intracranial pathology must be ruled out. Treating acute migraine is challenging because of substantial rates of nonresponse to medications and difficulty in predicting individual response to a specific agent or dose. Data comparing different drug classes are relatively scarce. Abortive therapy should be used as early as possible after the onset of symptoms. Effective first-line therapies for mild to moderate migraine are nonprescription nonsteroidal anti-inflammatory drugs and combination analgesics containing acetaminophen, aspirin, and caffeine. Triptans are first-line therapies for moderate to severe migraine, or mild to moderate migraine that has not responded to adequate doses of simple analgesics. Triptans should be avoided in patients with vascular disease, uncontrolled hypertension, or hemiplegic migraine. Intravenous antiemetics, with or without intravenous dihydroergotamine, are effective therapies in an emergency department setting. Dexamethasone may be a useful adjunct to standard therapy in preventing short-term headache recurrence. Intranasal lidocaine may also have a role in relief of acute migraine. Isometheptene-containing compounds and intranasal dihydroergotamine are also reasonable therapeutic options. Medications containing opiates or barbiturates should be avoided for acute migraine. During pregnancy, migraine may be treated with acetaminophen or nonsteroidal anti-inflammatory drugs (prior to third trimester), or opiates in refractory cases. Acetaminophen, ibuprofen, intranasal sumatriptan, and intranasal zolmitriptan seem to be effective in children and adolescents, although data in these age groups are limited.

Comment in

Similar articles

  • Management of the Acute Migraine Headache
    G Aukerman et al. Am Fam Physician 66 (11), 2123-30. PMID 12484694. - Review
    As many as 30 million Americans have migraine headaches. The impact on patients and their families can be tremendous, and treatment of migraines can present diagnostic an …
  • Rescue Therapy for Acute Migraine, Part 1: Triptans, Dihydroergotamine, and Magnesium
    NE Kelley et al. Headache 52 (1), 114-28. PMID 22211870. - Review
    Although there are relatively few studies involving health-care provider-administered triptans or DHE for acute rescue, they appear to be equivalent to the dopamine antag …
  • Migraine: Diagnosis, Management, and New Treatment Options
    RM Gallagher et al. Am J Manag Care 8 (3 Suppl), S58-73. PMID 11859906. - Review
    Primary care physicians must manage migraine patients with treatments that demonstrate a balance between efficacy and tolerability.
  • [Treatment Guidelines for Acute Migraine Attacks]
    Treatment Guideline Subcommittee of Taiwan Headache Society. Acta Neurol Taiwan 16 (4), 251-68. PMID 18220021.
    The Treatment Guideline Subcommittee of the Taiwan Headache Society evaluated the medications currently used for acute migraine attacks in Taiwan according to the princip …
  • Acute Management of Migraine
    D Chowdhury. J Assoc Physicians India 58 Suppl, 21-5. PMID 21049703.
    Migraine is a brain disease whose principal symptom is episodic intense throbbing pain in the head which is often accompanied by photophobia, phonophobia, nausea and vomi …
See all similar articles

Cited by 26 PubMed Central articles

See all "Cited by" articles
Feedback